Adagene (ADAG) News Today → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free ADAG Stock Alerts $2.37 +0.02 (+0.85%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMorgan Stanley lifts Adagene stock target on positive datainvesting.com - April 10 at 5:28 AMAdagene Inc.: Adagene Reports Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 31 at 10:52 AMAdagene Reports Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - March 29 at 9:00 AMAdagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Boardglobenewswire.com - March 7 at 4:01 PMAdagene to Present at the Leerink Partners Global Biopharma Conference 2024globenewswire.com - February 27 at 8:00 AMAdagene Inc. (NASDAQ:ADAG) Sees Significant Increase in Short Interestmarketbeat.com - February 12 at 10:52 AMAdagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)finance.yahoo.com - February 9 at 11:03 AMAdagene Inc. (NASDAQ:ADAG) Sees Large Decline in Short Interestmarketbeat.com - January 29 at 4:14 AMWeek In Review: Lee's Pharm Signs $138M Agreement For China Rights To Heart Failure Therapyseekingalpha.com - January 21 at 8:04 AMMesoblast rises after cell therapy gets FDA rare pediatric disease designationmsn.com - January 19 at 7:40 AMHow Is The Market Feeling About Adagene?benzinga.com - January 18 at 10:28 AMMorgan Stanley 'encouraged' by 2 cPRs reported by Adagenerealmoney.thestreet.com - January 17 at 1:09 PMWhy Is Cancer Focused Adagene Stock Plummeting Today?benzinga.com - January 17 at 1:09 PMAdagene falls after trial data for cancer therapymsn.com - January 17 at 1:09 PMAdagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)finance.yahoo.com - January 16 at 8:44 PMAdagene Inc.'s (NASDAQ:ADAG) market cap surged US$34m last week, retail investors who have a lot riding on the company were rewardedfinance.yahoo.com - January 10 at 6:26 AMAdagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposiumfinance.yahoo.com - January 4 at 9:29 AMNKGen doses first patient in Phase 1/2a Alzheimer's studymsn.com - December 28 at 7:11 PMAdagene price target lowered by 40c at Morgan Stanley, here's whyrealmoney.thestreet.com - December 20 at 12:26 AMDeka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directorsmarkets.businessinsider.com - December 19 at 2:19 PMAdagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023finance.yahoo.com - November 3 at 1:34 PMAre Medical Stocks Lagging Medpace (MEDP) This Year?finance.yahoo.com - October 13 at 3:06 PMAdagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meetingfinance.yahoo.com - October 12 at 12:49 PMAdagene Inc - ADR (ADAG) Price Target Increased by 9.87% to 14.04msn.com - October 5 at 10:02 AMAdagene’s Strong Potential: A Buy Rating Backed by Evorpacept Trials and Promising CD47-Targeted Therapiesmarkets.businessinsider.com - October 4 at 1:34 PMPotential Upside For Adagene Inc. (NASDAQ:ADAG) Not Without Riskfinance.yahoo.com - September 9 at 5:42 PMAdagene to Present at Investor and Scientific Conferences in Septemberfinance.yahoo.com - September 7 at 8:43 AMAdagene Reports Six Month Financial Results for 2023 and Provides Corporate Updatefinance.yahoo.com - August 31 at 8:45 AMArtificial Intelligence (AI) in Drug Discovery Market Revenue To Surpass USD 11,914 Million By 2030benzinga.com - August 8 at 6:37 PMAdvances in Cancer Immunotherapy: Breakthrough Techniques and Key Players Explored in New Reportfinance.yahoo.com - July 21 at 10:26 AMH.C. Wainwright Sticks to Its Buy Rating for LAVA Therapeutics (LVTX)markets.businessinsider.com - June 12 at 4:21 PMIs Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?finance.yahoo.com - May 25 at 3:19 PMAnalysts Are Bullish on These Healthcare Stocks: Poseida Therapeutics (PSTX), Mustang Bio (MBIO)markets.businessinsider.com - May 23 at 8:22 AMAdagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugatefinance.yahoo.com - May 4 at 1:23 PMAdagene Announces Updates to its Board of Directorsfinance.yahoo.com - April 28 at 9:33 AMHC Wainwright & Co. Reiterates Adagene Inc - ADR (ADAG) Buy Recommendationmsn.com - April 22 at 8:54 AMExpert Ratings for Adagenemarkets.businessinsider.com - April 21 at 7:57 PMAdagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumorsfinance.yahoo.com - April 18 at 12:57 PMAre Medical Stocks Lagging Adagene (ADAG) This Year?msn.com - March 31 at 4:41 PMAre Medical Stocks Lagging Adagene (ADAG) This Year?finance.yahoo.com - March 31 at 4:41 PMAdagene Full Year 2022 Earnings: US$1.85 loss per share (vs US$1.83 loss in FY 2021)finance.yahoo.com - March 31 at 9:52 AMAdagene Inc.: Adagene Reports Full Year 2022 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 29 at 4:43 PMAdagene Reports Full Year 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - March 28 at 7:00 PMH.C. Wainwright Sticks to Its Buy Rating for Adagene (ADAG)markets.businessinsider.com - March 21 at 8:09 AMH.C. Wainwright Keeps Their Buy Rating on Hookipa Pharma (HOOK)markets.businessinsider.com - March 16 at 8:42 AMAdagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in Aprilfinance.yahoo.com - March 14 at 9:06 PMShort Interest in Adagene Inc. (NASDAQ:ADAG) Decreases By 63.9%marketbeat.com - January 18 at 5:05 AMAdagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trialfinance.yahoo.com - January 9 at 9:22 AMAdagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9finance.yahoo.com - January 5 at 6:53 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC) and Adagene (ADAG)markets.businessinsider.com - December 22 at 8:49 AM Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom. 4 simple steps to protect your privacy and money before it’s too late. ADAG Media Mentions By Week ADAG Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADAG News Sentiment▼0.000.32▲Average Medical News Sentiment ADAG News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADAG Articles This Week▼00▲ADAG Articles Average Week Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IMUX News Today SCTL News Today ANVS News Today COYA News Today CTXR News Today INCR News Today CLRB News Today OPTN News Today RPTX News Today NVCT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADAG) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
